TY - JOUR
T1 - Cutaneous malignant melanoma after Hodgkin's disease
AU - Tucker, M. A.
AU - Misfeldt, D.
AU - Coleman, C. N.
AU - Clark, W. H.
AU - Rosenberg, S. A.
PY - 1985
Y1 - 1985
N2 - Eight cutaneous malignant melanomas occurred in 6 of 1405 patients with Hodgkin's disease, although the expected incidence rate was 0.77 (relative risk, 8; 95% confidence interval, 3 to 17). One melanoma was a thin, level II lesion less than 0.76 mm thick; the rest were mostly bulky, deeply invasive lesions despite close clinical surveillance. The melanomas spread aggressively; 3 of 6 patients died within 1 to 3 years. Two of the six patients developed a second primary malignant melanoma 1 year after the first. Two of six patients had biopsy-proven dysplastic nevus syndrome, a known precursor to cutaneous malignant melanoma, and an additional 3 patients had clinical evidence of dysplastic nevus syndrome. Histologically, the malignant melanomas showed a sparse inflammatory infiltrate, an abnormal host response seen previously in cutaneous melanomas developing in immunosuppressed patients. Dysplastic nevi may identify patients at highest risk who require modified medical management.
AB - Eight cutaneous malignant melanomas occurred in 6 of 1405 patients with Hodgkin's disease, although the expected incidence rate was 0.77 (relative risk, 8; 95% confidence interval, 3 to 17). One melanoma was a thin, level II lesion less than 0.76 mm thick; the rest were mostly bulky, deeply invasive lesions despite close clinical surveillance. The melanomas spread aggressively; 3 of 6 patients died within 1 to 3 years. Two of the six patients developed a second primary malignant melanoma 1 year after the first. Two of six patients had biopsy-proven dysplastic nevus syndrome, a known precursor to cutaneous malignant melanoma, and an additional 3 patients had clinical evidence of dysplastic nevus syndrome. Histologically, the malignant melanomas showed a sparse inflammatory infiltrate, an abnormal host response seen previously in cutaneous melanomas developing in immunosuppressed patients. Dysplastic nevi may identify patients at highest risk who require modified medical management.
UR - http://www.scopus.com/inward/record.url?scp=0021946915&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021946915&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-102-1-37
DO - 10.7326/0003-4819-102-1-37
M3 - Article
C2 - 3966743
AN - SCOPUS:0021946915
SN - 0003-4819
VL - 102
SP - 37
EP - 41
JO - Annals of internal medicine
JF - Annals of internal medicine
IS - 1
ER -